These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31381853)

  • 1. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
    Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
    J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
    Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
    J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
    Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
    Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel binding mode of a potent and selective tankyrase inhibitor.
    Gunaydin H; Gu Y; Huang X
    PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.
    Kumpan K; Nathubhai A; Zhang C; Wood PJ; Lloyd MD; Thompson AS; Haikarainen T; Lehtiö L; Threadgill MD
    Bioorg Med Chem; 2015 Jul; 23(13):3013-32. PubMed ID: 26026769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
    Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
    Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
    Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
    ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.
    Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C
    J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor.
    Ryu H; Nam KY; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Ahn J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the structure-based rational design of TNKSIs.
    Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
    Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.
    Thomson DW; Wagner AJ; Bantscheff M; Benson RE; Dittus L; Duempelfeld B; Drewes G; Krause J; Moore JT; Mueller K; Poeckel D; Rau C; Salzer E; Shewchuk L; Hopf C; Emery JG; Muelbaier M
    J Med Chem; 2017 Jul; 60(13):5455-5471. PubMed ID: 28591512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
    Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
    J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular insights on TNKS1/TNKS2 and inhibitor-IWR1 interactions.
    Kirubakaran P; Kothandan G; Cho SJ; Muthusamy K
    Mol Biosyst; 2014 Feb; 10(2):281-93. PubMed ID: 24291818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.
    Shultz MD; Cheung AK; Kirby CA; Firestone B; Fan J; Chen CH; Chen Z; Chin DN; Dipietro L; Fazal A; Feng Y; Fortin PD; Gould T; Lagu B; Lei H; Lenoir F; Majumdar D; Ochala E; Palermo MG; Pham L; Pu M; Smith T; Stams T; Tomlinson RC; Touré BB; Visser M; Wang RM; Waters NJ; Shao W
    J Med Chem; 2013 Aug; 56(16):6495-511. PubMed ID: 23844574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
    Qiu W; Lam R; Voytyuk O; Romanov V; Gordon R; Gebremeskel S; Vodsedalek J; Thompson C; Beletskaya I; Battaile KP; Pai EF; Rottapel R; Chirgadze NY
    Acta Crystallogr D Biol Crystallogr; 2014 Oct; 70(Pt 10):2740-53. PubMed ID: 25286857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
    Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
    J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
    Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
    Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
    Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
    Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
    Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
    Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.